Leading genetic testing company Illumina and next-generation sequencing (NGS) testing company Pillar Biosciences have formed a strategic partnership to make Pillar's suite of oncology assays globally available as part of Illumina's portfolio of oncology products.
The partnership allows the integration of Pillar's targeted sequencing technology with Illumina's advanced sequencing and bioinformatics solutions. This combination enables rapid and focused genomic profiling of tumors, aiding in personalized therapy for cancer patients.
The collaboration aims to enhance the efficiency, accuracy, and cost-effectiveness of oncology testing, providing patients with better access to personalized cancer treatment options. The commercial availability of Pillar's assays through Illumina is set to begin in July 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.